BioScrip Director Sells $39,700 in Stock (BIOS)
BioScrip (NASDAQ:BIOS) Director Myron Z. Holubiak sold 5,000 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $7.94, for a total value of $39,700.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $317,600. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of BioScrip (NASDAQ:BIOS) traded up 0.49% on Wednesday, hitting $8.17. The stock had a trading volume of 610,190 shares. BioScrip has a 1-year low of $5.61 and a 1-year high of $17.62. The stock has a 50-day moving average of $7.49 and a 200-day moving average of $7.45. The company’s market cap is $559.0 million. BioScrip also saw a large drop in short interest in the month of May. As of May 30th, there was short interest totalling 15,405,392 shares, a drop of 8.3% from the May 15th total of 16,800,846 shares. Based on an average trading volume of 1,028,079 shares, the short-interest ratio is currently 15.0 days. Approximately 23.4% of the company’s stock are sold short.
BioScrip (NASDAQ:BIOS) last released its earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.03) by $0.10. The company had revenue of $239.60 million for the quarter, compared to the consensus estimate of $222.65 million. Analysts expect that BioScrip will post $-0.09 EPS for the current fiscal year.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of BioScrip in a research note on Monday, April 14th. They now have a $7.50 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. BioScrip presently has an average rating of “Buy” and an average target price of $9.80.
BioScrip, Inc (NASDAQ:BIOS) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.